恒瑞医药涨超5% 注射用SHR-9839等9款药物获批开展临床试验

Core Viewpoint - Heng Rui Medicine (600276) (01276) saw a rise of over 5%, currently up 5.08% at HKD 69.3, with a trading volume of HKD 141 million [1] Group 1: Company Developments - On November 21, Heng Rui Medicine announced that it, along with its subsidiaries, received approval from the National Medical Products Administration for multiple clinical trial applications, including SHR-9839(sc), SHR-A2009, SHR-1826, HRS-4642 injection, and others [1] - The approved clinical trials will be conducted in the near future, indicating a proactive approach in expanding the company's product pipeline [1]